Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Woman shocked to welcome baby after experiencing stomach pain on Christmas - 2EPA watchdog finds nation’s most contaminated sites are vulnerable to flooding, wildfires
- 3Agricultural drones are taking off globally, saving farmers time and money
- 4Michael Jordan donates $10M to North Carolina medical center in honor of his mother
- 5The most effective method to Pick the Best Wellbeing Highlights for Seniors in SUVs
- How a Snake That Eats Cobras Redefined the Meaning of ‘King’
- The most effective method to Offset Album Rates with Liquidity Needs
- Meet the Artemis crew in NASA's first astronaut mission to the moon in more than a half-century
- Iconic iceberg turns blue, on verge of totally disintegrating, NASA says
- The Leonid meteor shower is peaking early this week. Here’s what to know
- How to watch 'A Charlie Brown Christmas' for less with this Apple TV Black Friday deal
- Polar bears are rewiring their own genetics to survive a warming climate
- IDF continues counterterrorism operations in Gaza Strip, including destroying terror tunnels
- Tablets: Upgrade Your Understanding Experience
